Genprex Inc (NASDAQ: GNPX)’s stock price has increased by 5.43 compared to its previous closing price of 0.31. However, the company has seen a 18.95% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-03 that AUSTIN, Texas, June 3, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance from Genprex’s executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The stock has a 36-month beta value of -0.40. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GNPX is 27.06M, and at present, short sellers hold a 9.19% of that float. On June 12, 2025, the average trading volume of GNPX was 4.65M shares.
GNPX’s Market Performance
The stock of Genprex Inc (GNPX) has seen a 18.95% increase in the past week, with a 15.11% rise in the past month, and a -9.89% fall in the past quarter. The volatility ratio for the week is 4.76%, and the volatility levels for the past 30 days are at 8.40% for GNPX. The simple moving average for the past 20 days is 12.24% for GNPX’s stock, with a -51.16% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at 14.80% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.83% of loss for the given period.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -1530.6 for the present operating margin
- -0.23 for the gross margin
The net margin for Genprex Inc stands at -1926.88. The total capital return value is set at -3.92. Equity return is now at value -302.69, with -205.73 for asset returns.
Currently, EBITDA for the company is -21.1 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 536.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.94.
Conclusion
To sum up, Genprex Inc (GNPX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
